• Latest Posts
In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Allgenesis says dry eye patients’ trial data ‘encouraging’

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Five ophthalmology biotech companies to look out for

Cell rejuvenation for age-related diseases

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover


Life Biosciences gene therapy data shows visual function restored in primates

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

Complement Therapeutics raises €72M for eye condition gene therapy

In Depth 3 Mar 2023

Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

Active Biotech trial confirms eye treatment safety